Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Pick the Right Old Consideration Administration: Key Contemplations - 2Iranian rockets hit Tel Aviv area, injuring six
- 3I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- 4Figure out What Shift Differentials Mean for Your General Attendant Compensation
- 5Extraordinary Snowboarding Objections All over the Planet
- Ski Resorts Universally: A Colder time of year Wonderland Guide
- Don’t let food poisoning crash your Thanksgiving dinner
- Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 'Stranger Things' made him a heartthrob. He left Hollywood anyway.
- The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- Divorce filings, feuds and legal trouble: The 'Mormon Wives' drama keeps piling up
- 2024 Style: The It-Things You Want in Your Closet
- Seoul says sorry after unapproved drone flights into North Korea
